Last reviewed · How we verify

prostaglandins E2 — Competitive Intelligence Brief

prostaglandins E2 (prostaglandins E2) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostanoid agonist. Area: Immunology / Regenerative Medicine.

phase 3 Prostanoid agonist EP prostanoid receptors (EP1, EP2, EP3, EP4) Immunology / Regenerative Medicine Small molecule Live · refreshed every 30 min

Target snapshot

prostaglandins E2 (prostaglandins E2) — Tel-Aviv Sourasky Medical Center. Prostaglandin E2 (PGE2) binds to EP prostanoid receptors on cell surfaces to modulate inflammation, immune responses, and tissue remodeling.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
prostaglandins E2 TARGET prostaglandins E2 Tel-Aviv Sourasky Medical Center phase 3 Prostanoid agonist EP prostanoid receptors (EP1, EP2, EP3, EP4)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostanoid agonist class)

  1. Tel-Aviv Sourasky Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). prostaglandins E2 — Competitive Intelligence Brief. https://druglandscape.com/ci/prostaglandins-e2. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: